{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:22:11Z","timestamp":1792657331336,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006127","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,1,31]],"date-time":"2015-01-31T00:00:00Z","timestamp":1422662400000}}],"reference-count":168,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006127.pub2","type":"journal-article","created":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T04:01:32Z","timestamp":1422936092000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Blood pressure control for diabetic retinopathy"],"prefix":"10.1002","author":[{"given":"Diana V","family":"Do","sequence":"first","affiliation":[{"name":"University of Nebraska Medical Center; Stanley M. Truhlsen Eye Institute; 985540 Nebraska Medical Center Omaha Nebraska USA 68198-5540"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health; Department of Epidemiology; 615 N. Wolfe Street Baltimore Maryland USA 21205"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyanarayana S","family":"Vedula","sequence":"additional","affiliation":[{"name":"Johns Hopkins University; 3400 N. Charles Street Baltimore Maryland USA 21218"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Marrone","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health; Department of Epidemiology; 615 N. Wolfe Street Baltimore Maryland USA 21205"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Sleilati","sequence":"additional","affiliation":[{"name":"Clemenceau Medical Center; Affiliated with Johns Hopkins International Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine; Wilmer Eye Institute; 550 North Broadway, 9th floor Baltimore Maryland USA 21205-2010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N","family":"Frank","sequence":"additional","affiliation":[{"name":"Kresge Eye Institute; Department of Ophthalmology; Wayne State University School of Medicine 4717 St. Antoine Boulevard Detroit Michigan USA 48201"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,1,31]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD006127.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","article-title":"Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes","volume":"61","author":"Schrier","year":"2002","journal-title":"Kidney International"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s001250050629","article-title":"Appropriate Blood Pressure Control in NIDDM (ABCD) Trial","volume":"39","author":"Schrier","year":"1996","journal-title":"Diabetologia"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0272-6386(12)70236-6","article-title":"Appropriate Blood Pressure Control in Type II Diabetes (ABCD Trial): implications for complications","volume":"20","author":"Schrier","year":"1992","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006127.pub2-BIB0004|cit4","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23","author":"Estacio","year":"2000","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","article-title":"The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension","volume":"338","author":"Estacio","year":"1998","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006127.pub2-BIB0006|cit6","first-page":"Doc No 104","article-title":"The ABCD (Appropriate Blood Pressure Control in Diabetes) Trial. Rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes","author":"Savage","journal-title":"Online Journal of Current Clinical Trials"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/archophthalmol.2009.310","article-title":"Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy","volume":"128","author":"Ambrosius","year":"2010","journal-title":"Archives of Ophthalmology"},{"issue":"12A","key":"10.1002\/14651858.CD006127.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"21i","DOI":"10.1016\/j.amjcard.2007.03.003","article-title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: design and methods","volume":"99","author":"Buse","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub2-BIB0011|cit9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1011499","article-title":"Update of the ACCORD Eye Study","volume":"364","author":"Chew","year":"2011","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub2-BIB0009|cit10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"12A","key":"10.1002\/14651858.CD006127.pub2-BIB0010|cit11","doi-asserted-by":"crossref","first-page":"103i","DOI":"10.1016\/j.amjcard.2007.03.028","article-title":"Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE)","volume":"99","author":"Chew","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"12A","key":"10.1002\/14651858.CD006127.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"44i","DOI":"10.1016\/j.amjcard.2007.03.005","article-title":"Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"99","author":"Cushman","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"9739","key":"10.1002\/14651858.CD006127.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/ki.2011.415","article-title":"Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients","volume":"81","author":"Ismail-Beigi","year":"2012","journal-title":"Kidney International"},{"issue":"12A","key":"10.1002\/14651858.CD006127.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"90i","DOI":"10.1016\/j.amjcard.2007.03.027","article-title":"Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design","volume":"99","author":"Sullivan","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1464-5491.2005.01596.x","article-title":"ADVANCE - Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline","volume":"22","author":"ADVANCE Collaborative Group","year":"2005","journal-title":"Diabetic Medicine"},{"issue":"9590","key":"10.1002\/14651858.CD006127.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"ADVANCE Collaborative Group","year":"2007","journal-title":"Lancet"},{"issue":"24","key":"10.1002\/14651858.CD006127.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"ADVANCE Collaborative Group","year":"2008","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD006127.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s001250100612","article-title":"Study rationale and design of ADVANCE: Action in Diabetes and Vascular Disease - preterax and diamicron MR controlled evaluation","volume":"44","author":"ADVANCE Management Committee","year":"2001","journal-title":"Diabetologia"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00125-009-1457-x","article-title":"Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"52","author":"Beulens","year":"2009","journal-title":"Diabetologia"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1046\/j.1440-1681.2001.03581.x","article-title":"Blood pressure lowering in diabetes: a brief review of current evidence and description of a new trial","volume":"28","author":"Patel","year":"2001","journal-title":"Clinical and Experimental Pharmacology and Physiology"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.hjh.0000354417.70192.be","article-title":"Blood pressure and glucose control in subject with diabetes: new analysis from ADVANCE","volume":"27","author":"Poulter","year":"2009","journal-title":"Journal of Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cct.2006.08.011","article-title":"Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus","volume":"28","author":"Stolk","year":"2007","journal-title":"Contemporary Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2337\/dc07-1657","article-title":"Retinal vascular lesions in patients of Caucasian and Asian origin with type 2 diabetes: baseline results from the ADVANCE Retinal Measurements (AdRem) study","volume":"31","author":"Stolk","year":"2008","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0197-2456(03)00028-X","article-title":"The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT)","volume":"24","author":"BENEDICT Group","year":"2003","journal-title":"Controlled Clinical Trials"},{"issue":"19","key":"10.1002\/14651858.CD006127.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006127.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"Article ID 1063","DOI":"10.1155\/2010\/106384","article-title":"Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trial","volume":"2010","author":"Ruggenenti","year":"2010","journal-title":"Journal of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub2-BIB0028|cit28","first-page":"284","article-title":"Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial","volume":"25","author":"Chase","year":"1993","journal-title":"Annals of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/HYPERTENSIONAHA.111.174474","article-title":"Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) randomized clinical trial","volume":"58","author":"Ruggenenti","year":"2011","journal-title":"Hypertension"},{"issue":"9647","key":"10.1002\/14651858.CD006127.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","article-title":"Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials","volume":"372","author":"Chaturvedi","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3317\/jraas.2002.047","article-title":"The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme, rationale and study design","volume":"3","author":"Chaturvedi","year":"2002","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3317\/jraas.2005.003","article-title":"The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics","volume":"6","author":"DIRECT Programme Study Group","year":"2005","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1464-5491.2010.03210.x","article-title":"Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme","volume":"28","author":"Sjolie","year":"2011","journal-title":"Diabetic Medicine"},{"issue":"9647","key":"10.1002\/14651858.CD006127.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","article-title":"Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials","volume":"372","author":"Chaturvedi","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3317\/jraas.2002.047","article-title":"DIabetic REtinopathy Candesartan Trials (DIRECT) Programme, rationale and study design","volume":"3","author":"Chaturvedi","year":"2002","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3317\/jraas.2005.003","article-title":"DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics","volume":"6","author":"DIRECT Programme Study Group","year":"2005","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3317\/jraas.2002.047","article-title":"DIabetic REtinopathy Candesartan Trials (DIRECT) Programme, rationale and study design","volume":"3","author":"Chaturvedi","year":"2002","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3317\/jraas.2005.003","article-title":"DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics","volume":"6","author":"DIRECT Programme Study Group","year":"2005","journal-title":"Journal of Renin-Angiotensin-Aldosterone System"},{"issue":"9647","key":"10.1002\/14651858.CD006127.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(08)61411-7","article-title":"Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial","volume":"372","author":"Sjolie","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1464-5491.2001.00441.x","article-title":"Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition","volume":"18","author":"Chaturvedi","year":"2001","journal-title":"Diabetes Medicine"},{"issue":"9095","key":"10.1002\/14651858.CD006127.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(97)06209-0","article-title":"Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes","volume":"351","author":"Chaturvedi","year":"1998","journal-title":"Lancet"},{"issue":"9068","key":"10.1002\/14651858.CD006127.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(96)10244-0","article-title":"Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria","volume":"349","author":"EUCLID Study Group","year":"1997","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub2-BIB0043|cit43","first-page":"949","article-title":"Effect of lisinopril on progression of retinopathy and microalbuminuria in normotensive subjects with insulin-dependent diabetes mellitus","volume":"161","author":"Sjolie","year":"1999","journal-title":"Ugeskrift for Laeger"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0161-6420(97)30327-3","article-title":"Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study","volume":"104","author":"Sjolie","year":"1997","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1056-8727(02)00188-5","article-title":"Angiotensin-converting enzyme inhibition for the treatment of moderate to severe diabetic retinopathy in normotensive type 2 diabetic patients. A pilot study","volume":"16","author":"Pradhan","year":"2002","journal-title":"Journal of Diabetes and Its Complications"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.ophtha.2006.06.003","article-title":"The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus.\u00a0The Renin-Angiotensin System Study","volume":"113","author":"Klein","year":"2006","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2337\/diabetes.54.2.527","article-title":"The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients. The Renin-Angiotensin System Study","volume":"54","author":"Klein","year":"2005","journal-title":"Diabetes"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3317\/jraas.2002.048","article-title":"ACE-I and ARBs in early diabetic retinopathy","volume":"3","author":"Mauer","year":"2002","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"The New England Journal of Medicine"},{"issue":"9153","key":"10.1002\/14651858.CD006127.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006127.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4158\/EP.12.S1.89","article-title":"Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study","volume":"12","author":"Vaag","year":"2006","journal-title":"Endocrine Practice"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s00125-005-1717-3","article-title":"Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)","volume":"48","author":"Clarke","year":"2005","journal-title":"Diabetologia"},{"issue":"7369","key":"10.1002\/14651858.CD006127.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/bmj.325.7369.860","article-title":"Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63)","volume":"325","author":"Gray","year":"2002","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1464-5491.2001.00485.x","article-title":"An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54)","volume":"18","author":"Gray","year":"2001","journal-title":"Diabetes Medicine"},{"issue":"15","key":"10.1002\/14651858.CD006127.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","article-title":"Long-term follow-up after tight control of blood pressure in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1464-5491.1994.tb00352.x","article-title":"Hypertension in Diabetes Study III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and \u00df-blockade","volume":"11","author":"Hypertension in Diabetes Study Group","year":"1994","journal-title":"Diabetic Medicine"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1007\/s001250050614","article-title":"Hypertension in Diabetes Study IV.\u00a0 Therapeutic requirements to maintain tight blood pressure control","volume":"39","author":"Hypertension in Diabetes Study Group","year":"1996","journal-title":"Diabetologia"},{"issue":"9","key":"10.1002\/14651858.CD006127.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s001250051278","article-title":"Microaneurysms in the development of diabetic retinopathy (UKPDS 42)","volume":"42","author":"Kohner","year":"1999","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s001250051594","article-title":"UKPDS 50: Risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis","volume":"44","author":"Stratton","year":"2001","journal-title":"Diabetologia"},{"issue":"9131","key":"10.1002\/14651858.CD006127.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"7160","key":"10.1002\/14651858.CD006127.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/bmj.317.7160.720","article-title":"Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"issue":"7160","key":"10.1002\/14651858.CD006127.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2337\/diacare.22.7.1125","article-title":"Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37)","volume":"22","author":"UK Prospective Diabetes Study Group","year":"1999","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1002\/14651858.CD006127.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/archopht.122.11.1631","article-title":"Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus. UKPDS 69","volume":"122","author":"UK Prospective Diabetes Study Group","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"7160","key":"10.1002\/14651858.CD006127.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/BF00400195","article-title":"UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance","volume":"34","author":"UK Prospective Diabetes Study Group","year":"1991","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD006127.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1447-0594.2011.00808.x","article-title":"Long-term multiple risk factor interventions in Japanese elderly diabetic patients: the Japanese Elderly Diabetes Intervention Trial-study design, baseline characteristics and effects of intervention","volume":"12 Suppl 1","author":"Araki","year":"2012","journal-title":"Geriatrics and Gerontology International"},{"key":"10.1002\/14651858.CD006127.pub2-BIB0069|cit69","unstructured":"Auyanet I Rodriguez LJ Esparza N Cabrera F Rossique P Suria S Does carvedilol minimize the requirements for laser photocoagulation in diabetic retinopathy? Nefrologia 2010 473 4"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3317\/jraas.2003.019","article-title":"Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design","volume":"4","author":"Andersen","year":"2003","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2337\/diacare.28.2.273","article-title":"Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study","volume":"28","author":"Andersen","year":"2005","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.2040-1124.2010.00085.x","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes: Is blood pressure control the lower the better?","volume":"2","author":"Chang","year":"2011","journal-title":"Journal of Diabetes Investigation"},{"issue":"19","key":"10.1002\/14651858.CD006127.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1001\/jama.287.19.2563","article-title":"Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus","volume":"287","author":"Genuth","year":"2002","journal-title":"JAMA"},{"issue":"14","key":"10.1002\/14651858.CD006127.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0002-9149(99)80683-3","article-title":"Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial","volume":"75","author":"The Diabetes Control and Complications Trial Research Group","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2337\/diacare.22.1.99","article-title":"Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort","volume":"22","author":"The Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Research Group","year":"1999","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub2-BIB0076|cit76","first-page":"1085","article-title":"Evaluation of retinal involvement in type 2 diabetics with microalbuminuria","volume":"128","author":"Durruty","year":"2000","journal-title":"Revista Medica de Chile"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0077|cit77","first-page":"690","article-title":"Metabolic controlled trial of nicardipine in type 2 diabetic patients with slight hypertension","volume":"45","author":"Faguer de Moustier","year":"1989","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2337\/diab.18.5.285","article-title":"A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy","volume":"18","author":"Harrold","year":"1969","journal-title":"Diabetes"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub2-BIB0079|cit79","first-page":"99","article-title":"Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy","volume":"24","author":"Jackson","year":"1992","journal-title":"Annals of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD006127.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-011-2199-0","article-title":"Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow-up study of the Japan Diabetes Complications Study (JDCS)","volume":"54","author":"Kawasaki","year":"2011","journal-title":"Diabetologia"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00125-009-1622-2","article-title":"Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study)","volume":"53","author":"Sone","year":"2010","journal-title":"Diabetologia"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/BF00918480","article-title":"Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy","volume":"228","author":"Larsen","year":"1990","journal-title":"Graefe's Archive of Clinical and Experimental Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0083|cit83","first-page":"18","article-title":"On the prospective significance of age at onset of diabetes, metabolic control, and hypertension for the development of diabetic retinopathy in patients with IDDM","volume":"5","author":"Lehsten","year":"1996","journal-title":"Diabetes und Stoffwechsel"},{"issue":"9145","key":"10.1002\/14651858.CD006127.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/S0140-6736(98)02478-7","article-title":"Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy:\u00a0randomised double-blind controlled trial","volume":"352","author":"Malik","year":"1998","journal-title":"Lancet"},{"issue":"7011","key":"10.1002\/14651858.CD006127.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/bmj.311.7011.973","article-title":"Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria","volume":"311","author":"Microalbuminuria Collaborative Study Group","year":"1995","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1755-3768.2009.01847.x","article-title":"Lack of effect of short-term treatment with amlodipine and lisinopril on retinal autoregulation in normotensive patients with type 1 diabetes and mild diabetic retinopathy","volume":"89","author":"Mehlsen","year":"2011","journal-title":"Acta Ophthalmologica"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/112067219100100305","article-title":"The effect of beta blockers on retinal blood flow in diabetic patients","volume":"1","author":"Newsom","year":"1991","journal-title":"European Journal of Ophthalmology"},{"issue":"12 Suppl 1","key":"10.1002\/14651858.CD006127.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0026-0495(98)90368-7","article-title":"Effect of angiotensin-converting enzyme inhibition with perindopril and beta-blockade with atenolol on retinal blood flow in hypertensive diabetic subjects","volume":"47","author":"Patel","year":"1998","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"B","key":"10.1002\/14651858.CD006127.pub2-BIB0089|cit89","first-page":"B22","article-title":"The benefits of angiotensin II receptor antagonists in high-risk hypertensive patients with diabetes","volume":"2","author":"Porush","year":"2000","journal-title":"European Heart Journal Supplements"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0953-6205(99)00068-0","article-title":"Effect of enalapril on the incidence of retinopathy in normotensive patients with type 2 diabetes","volume":"11","author":"Rachmani","year":"2000","journal-title":"European Journal of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1464-5491.2002.00701.x","article-title":"Teaching patients to monitor their risk factors retards the progression of vascular complications in high-risk patients with type 2 diabetes mellitus-a randomized prospective study","volume":"19","author":"Rachmani","year":"2002","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD006127.pub2-BIB0092|cit92","unstructured":"Rassam SMB Patel VJ Kohner E Effect of ACE-inhibitors on retinopathy score and retinal hemodynamics in normotensive diabetic subjects American Academy of Ophthalmology 1997 207"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1093\/ndt\/13.10.2547","article-title":"Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy","volume":"13","author":"Schwartz","year":"1998","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub2-BIB0094|cit94","first-page":"287","article-title":"Treatment effects of captopril on non-proliferative diabetic retinopathy","volume":"125","author":"Wang","year":"2012","journal-title":"Chinese Medical Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006127.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3317\/JRAAS.2000.050","article-title":"Improving the prognosis of diabetic patients: evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor block (ARB) therapy","volume":"1","author":"Bedigian","year":"2000","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD006127.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"56A","DOI":"10.1016\/S0895-7061(00)00436-2","article-title":"Baseline characteristics of the hypertensive cohort of the appropriate blood pressure control in diabetes trial - part 2 with valsartan (ABCD-2V)","volume":"13","author":"Bedigian","year":"2000","journal-title":"American Journal of Hypertension"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.amjhyper.2006.05.011","article-title":"Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes","volume":"19","author":"Estacio","year":"2006","journal-title":"American Journal of Hypertension"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD006127.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"141A","DOI":"10.1016\/S0895-7061(99)80501-9","article-title":"ABCD-2V: Appropriate blood pressure control in diabetes - part 2 with valsartan","volume":"12","author":"Shrier","year":"1999","journal-title":"American Journal of Hypertention"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc13-1544","article-title":"Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: The ADDITION-Europe Study","volume":"37","author":"Sandbaek","year":"2014","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/01.hjh.0000202820.56201.e6","article-title":"Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study","volume":"24","author":"Haller","year":"2006","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD006127.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-2431-9-79","article-title":"Adolescent type 1 diabetes cardio-renal intervention trial (AdDIT)","volume":"9","author":"AdDIT Research Group","year":"2009","journal-title":"BMC Pediatrics"},{"key":"10.1002\/14651858.CD006127.pub2-BIB0102|cit102","unstructured":"NCT00134160 The study comparing the incidence of cardiovascular events between high-dose ARB monotherapy and combination therapy with ARB and calcium channel blocker in Japanese elderly hypertensive patients at high cardiovascular risk clinicaltrials.gov\/ct2\/show\/NCT00134160"},{"key":"10.1002\/14651858.CD006127.pub2-BIB0103|cit103","unstructured":"NCT00300976 A randomized controlled study of the intensive therapy and the conventional therapy for the suppression of the vascular complications in the type 2 diabetic patients clinicaltrials.gov\/ct2\/show\/NCT00300976"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2337\/diacare.21.1.157","article-title":"Diabetic retinopathy","volume":"21","author":"American Diabetes Association","year":"1998","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2003.05.010","article-title":"Prevalence and causes of visual impairment and blindness among Scandinavian adults: the Copenhagen City Eye Study","volume":"111","author":"Buch","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD006127.pub2-BIB0106|cit106","unstructured":"Centers for Disease Control and Prevention National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011"},{"issue":"9","key":"10.1002\/14651858.CD006127.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archopht.1996.01100140281004","article-title":"Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22","volume":"114","author":"Chew","year":"1996","journal-title":"Archives of Ophthalmology"},{"issue":"12A","key":"10.1002\/14651858.CD006127.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"44i","DOI":"10.1016\/j.amjcard.2007.03.005","article-title":"Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"99","author":"Cushman","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"14","key":"10.1002\/14651858.CD006127.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub2-BIB0110|cit110","first-page":"1","article-title":"Trends in vision and hearing among older Americans","author":"Desai","year":"2001","journal-title":"Aging Trends"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub2-BIB0112|cit112","first-page":"983","article-title":"Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) report number 10","volume":"26","author":"Rand","year":"1985","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0161-6420(78)35693-1","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings","volume":"85","author":"The Diabetes Retinopathy Study Research Group","year":"1978","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD006127.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000395330","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic Retinopathy Study report number 5","volume":"2","author":"The Diabetic Retinopathy Study Research Group","year":"1981","journal-title":"Developments in Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub2-BIB0115|cit115","first-page":"583","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings. DRS report number 8","volume":"88","author":"The Diabetic Retinopathy Study Research Group","year":"1981","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"The Eye Diseases Prevalence Research Group","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archopht.122.4.552","article-title":"The prevalence of diabetic retinopathy among adults in the United States","volume":"122","author":"The Eye Diseases Prevalence Research Group","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/archopht.122.4.546","article-title":"The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States","volume":"122","author":"The Eye Diseases Prevalence Research Group","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1","volume":"103","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1985","journal-title":"Archives of Ophthalmology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD006127.pub2-BIB0120|cit120","first-page":"786","article-title":"Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD006127.pub2-BIB0121|cit121","first-page":"823","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub2-BIB0122|cit122","first-page":"233","article-title":"Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report number 18","volume":"39","author":"Davis","year":"1998","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD006127.pub2-BIB0123|cit123","first-page":"766","article-title":"Early photocoagulation for diabetic retinopathy. ETDRS report number 9","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jama.1993.03500100088034","article-title":"How effective are treatments for diabetic retinopathy?","volume":"269","author":"Ferris","year":"1993","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006127.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.2337\/diacare.27.2007.S84","article-title":"Retinopathy in diabetes","volume":"27","author":"Fong","year":"2004","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra021678","article-title":"Medical progress: diabetic retinopathy","volume":"350","author":"Frank","year":"2004","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD006127.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/bjo.83.9.1083","article-title":"Hypertension and diabetic retinopathy--what's the story?","volume":"83","author":"Gillow","year":"1999","journal-title":"British Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00417-004-0880-4","article-title":"Prevalence and risk factors of diabetic retinopathy in adult and elderly subjects: The Castedaccia Eye Study","volume":"242","author":"Giuffre","year":"2004","journal-title":"Graefe's Archives of Clinical and Experimental Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub2-BIB0129|cit129","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/bjo.73.2.88","article-title":"Blind and partial sight registration in Avon","volume":"73","author":"Grey","year":"1989","journal-title":"British Journal of Ophthalmology"},{"issue":"9118","key":"10.1002\/14651858.CD006127.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.2337\/diacare.21.8.1230","article-title":"Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type-2 diabetes? A US population study","volume":"21","author":"Harris","year":"1998","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.0742-3071.2001.00603.x","article-title":"What is the prevalence of visual impairment in the general and diabetic populations: are there ethnic and gender differences?","volume":"19","author":"Hayward","year":"2002","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD006127.pub2-BIB0134|cit134","unstructured":"Higgins JPT Altman DG (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"9200","key":"10.1002\/14651858.CD006127.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub-study","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006127.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1007\/PL00002935","article-title":"The appearance of retinopathy and progression to proliferative retinopathy: the WHO multinational study of vascular disease in diabetes","volume":"44","author":"Keen","year":"2001","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archopht.1984.01040030398010","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years","volume":"102","author":"Klein","year":"1984","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/archopht.1984.01040030405011","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years","volume":"102","author":"Klein","year":"1984","journal-title":"Archives of Ophthalmology"},{"issue":"19","key":"10.1002\/14651858.CD006127.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.1988.03410190112033","article-title":"Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy","volume":"260","author":"Klein","year":"1988","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/S0161-6420(89)32699-6","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy XI. The incidence of macular edema","volume":"96","author":"Klein","year":"1989","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD006127.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1001\/archinte.1989.00390110033008","article-title":"Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?","volume":"149","author":"Klein","year":"1989","journal-title":"Archives of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bjo.86.4.365","article-title":"Blood pressure control and diabetic retinopathy","volume":"86","author":"Klein","year":"2002","journal-title":"British Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0161-6420(02)01074-6","article-title":"The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study","volume":"109","author":"Klein","year":"2002","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2337\/diacare.26.1.76","article-title":"Incidence of retinopathy and nephropathy in youth-onset compared with adult-onset type 2 diabetes","volume":"26","author":"Krakoff","year":"2003","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000027415","article-title":"Blindness incidence in Germany. A population-based study from Wurttemberg-Hohenzollern","volume":"213","author":"Krumpaszky","year":"1999","journal-title":"Ophthalmologica"},{"issue":"11","key":"10.1002\/14651858.CD006127.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1046\/j.1464-5491.2002.00839.x","article-title":"Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with type 1 diabetes","volume":"19","author":"Kullberg","year":"2002","journal-title":"Diabetes Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0161-6420(03)00086-1","article-title":"Incidence of diabetic retinopathy in the Barbados Eye Studies","volume":"110","author":"Leske","year":"2003","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute Visual Function Questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Archives of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jama.298.8.902","article-title":"Management of diabetic retinopathy. A systematic review","volume":"298","author":"Mohamed","year":"2007","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD006127.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0161-6420(96)30486-7","article-title":"Cigarette smoking and ten-year progression in diabetic retinopathy","volume":"103","author":"Moss","year":"1996","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s001250100030","article-title":"Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study","volume":"44","author":"Porta","year":"2001","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD006127.pub2-BIB0152|cit152","unstructured":"American Academy of Ophthalmology Retina Panel Preferred Practice Patterns\u00ae Guidelines. Diabetic Retinopathy San Francisco, CA American Academy of Ophthalmology"},{"key":"10.1002\/14651858.CD006127.pub2-BIB0153|cit153","unstructured":"The Nordic Cochrane Center, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1600-0420.1996.tb00716.x","article-title":"Current trends in newly registered blindness in Denmark","volume":"74","author":"Rosenberg","year":"1996","journal-title":"Acta Ophthalmologica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.survophthal.2012.01.004","article-title":"Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective","volume":"57","author":"Sivaprasad","year":"2012","journal-title":"Survey of Opthalmology"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1742-1241.2010.02552.x","article-title":"Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review","volume":"65","author":"Sj\u00f8lie","year":"2011","journal-title":"International Journal of Clinical Practice"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub2-BIB0157|cit157","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008214.pub2","article-title":"Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy","author":"Smith","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2337\/diacare.26.6.1731","article-title":"The prevalence of and factors associated with diabetic retinopathy in the Australian population","volume":"26","author":"Tapp","year":"2003","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/bjophthalmol-2013-304017","article-title":"Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service","volume":"99","author":"Thomas","year":"2015","journal-title":"British Journal of Ophthalmology"},{"issue":"9131","key":"10.1002\/14651858.CD006127.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"Lancet"},{"issue":"7160","key":"10.1002\/14651858.CD006127.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2337\/diacare.25.8.1320","article-title":"Blood pressure, lipids, and obesity are associated with retinopathy: The Hoorn Study","volume":"25","author":"Leiden","year":"2002","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/archopht.121.2.245","article-title":"Risk factors for incident retinopathy in a diabetic and non-diabetic population: The Hoorn Study","volume":"121","author":"Leiden","year":"2003","journal-title":"Archives of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub2-BIB0164|cit164","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub4","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema","author":"Virgili","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2337\/diacare.24.7.1275","article-title":"Risk of developing retinopathy in Diabetes Control and Complication Trial type 1 diabetic patients with good or poor metabolic control","volume":"24","author":"Zhang","year":"2001","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jama.2010.1111","article-title":"Prevalence of diabetic retinopathy in the United States, 2005-2008","volume":"304","author":"Zhang","year":"2010","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub2-BIB0168|cit168","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006127","article-title":"Blood pressure control for diabetic retinopathy","author":"Sleilati","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006127.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006127.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T23:56:22Z","timestamp":1717718182000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006127.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,1,31]]},"references-count":168,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006127.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD006127.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,31]]}}}